Grannus Therapeutics

What it does

"Grannus Therapeutics is a pioneering lifetech startup dedicated to developing innovative Hsp90β-selective inhibitors for the treatment of multiple solid tumors. By focusing on a specific isoform of the Hsp90 chaperone protein, Grannus Therapeutics aims to overcome the toxicity challenges faced by previous pan-inhibitors, leading to more effective and targeted cancer treatments. Their pipeline of first-in-class small molecule inhibitors is designed to deliver potent anti-tumor efficacy without the dose-limiting side effects associated with traditional Hsp90 inhibitors. These compounds show promise in treating various solid tumors, including ovarian, triple-negative breast, prostate, and pancreatic cancers. With the potential for combination therapies with existing cancer treatments, such as chemotherapy and PARP inhibitors, Grannus Therapeutics is at the forefront of advancing oncology research and improving patient outcomes."